Thursday - 24 May 2012
South San Francisco Conference Center
http://personalizedmedicine.sfsu.edu

Speakers Biographies

Steven M. Anderson, Ph.D., Chief Scientific Officer, Oncology & Genetics, Monogram Biosciences/LabCorp
Dr. Steven Anderson has served in a variety of technical director positions for LabCorp during his 20-year tenure including positions at the Center for Molecular Biology and Pathology and ViroMed Laboratories. He participated in the development and validation of commonly used diagnostic assays that employ methods such as immunohistochemistry and fluorescence in situ hybridization (FISH) and molecular biology methods that characterize mutations and gene expression levels. He has authored more than 150 articles and abstracts.

Tom Anderton, V.P., Intellectual Property and Legal Affairs, Presidio Pharmaceuticals, Inc.
Tom Anderton earned his B.S. in Molecular Biology at the University of California, San Diego, and a M.S. in Cancer Biology from Stanford University. He attended law school and received a J.D. from the Vermont Law School. Tom is a member of the State Bar of California and is registered to practice before the United States Patent and Trademark Office. He has over 15 years of experience in developing and implementing intellectual property portfolios and legal strategy. Before joining Presidio Pharmaceuticals, he was an Associate General Counsel at Monogram Biosciences, Inc. where he was responsible for developing and implementing an IP portfolio related to oncology and virology. Prior to Monogram, Tom was the Lead Attorney for Genencor’s Oncology section where he developed and implemented the oncology IP portfolio and led legal affairs for Health Care.

Dr. Colin Collins, Senior Scientist, Vancouver Prostate Centre
Dr. Collins is an associate adjunct professor at the University of California San Francisco’s Helen Diller Family Comprehensive Cancer Center. His research focuses on translational genomics where mathematics, computer science, genomics and clinical science converge in systems biology, diagnostics, and ultimately therapeutics. He is currently combining novel computational methods with massively parallel sequencing to explore the mechanisms of prostate cancer progression including development of resistance to therapy. To date this work has resulted in identification of a new type of prostate cancer, sequence-based pathology, and a pilot study of personalized oncology that combined a patient-derived xenograft with a novel therapeutic strategy. His work as a member of the UCSF Prostate Specialized Program resulted in identification and patenting of a suite of genome based biomarkers that show promise for predicting a patient’s risk of progression to metastasis.
**David Ewing Duncan**, Biotechnology Correspondent, TechNation, Author, Experimental Man, Director, Center for Life Science Policy, University of California, Berkeley

David Ewing Duncan is an award-winning, best-selling author of seven books published in 19 languages. His most recent book is the bestseller Experimental Man: What one man’s body reveals about his future, your health, and our toxic world. David has won numerous awards including the Magazine Story of the Year from the American Association for the Advancement of Science. His articles have appeared in The New York Times, Fortune, Wired, National Geographic, Discover, and Atlantic Monthly, have twice been nominated for National Magazine Awards, and appeared twice in The Best American Science and Nature Writing. David is also a television, radio and film producer and Chief Correspondent for National Public Radio’s Biotech Nation, and a former special correspondent and producer for ABC Nightline and NOVA’s ScienceNOW! He is the Founding Director of the Center of Life Science Policy at UC Berkeley. He is currently at work on a TED book on extreme aging.

**Dr. Cristina Gentillini**, Research Scientist, Swedish Biomimetics 3000

Dr. Gentillini earned her Ph.D. in Chemistry at the University of Trieste in Italy where she acquired experience in the synthesis of metallic nanoparticles protected by organic molecules. During her postdoctoral training at Imperial College in London, she worked on the design and synthesis of polymeric biomaterials for regenerative medicine applications and peptide-functionalized nanomaterials for biosensing. Dr. Gentillini currently works on platform technologies and the development of an application portfolio with a focus on personalized medicine.

**Brian Kennedy, Ph.D.**, CEO, Buck Institute for Age Research

Dr. Brian Kennedy has an international reputation for his work on the basic biology of aging. He earned his Ph.D. from the Massachusetts Institute of Technology, and is well known for the work he did during his graduate studies with Leonard Guarente PhD which led to the discovery that Sirtuins (SIR2) modulate aging. His current work involves nutrient signaling pathways linked to dietary restriction, particularly the TOR pathway. He also studies A-type nuclear lamins which are targets for mutation in Hutchinson-Gilford progeria syndrome. Before joining the Buck Institute in 2010, he taught in the Department of Biochemistry at the University of Washington in Seattle. He currently serves on the National Institutes of Health’s Cellular Mechanisms of Aging and Development study section, and on the grant review committee for the American Federation for Aging Research Grants. He has published more than 60 manuscripts in many prestigious journals including Cell, Nature, Science, and the Proceedings of the National Academy of Sciences. He is an Associate Editor for the Journal of Gerontology, and is a consultant for biotech and pharmaceutical companies.

**Richard M. Lawn, Ph.D.**, Executive Director, Translational Medicine, SomaLogic, Inc.

Dr. Lawn’s post-doctoral research at the California Institute of Technology featured the construction of the first human genomic DNA library, the characterization of the globin genes, and the first human genes isolated and analyzed at the genomic DNA level. At Genentech he led the successful isolation and characterization of the factor VIII gene and production of recombinant factor VIII protein. He is the winner of numerous awards including the Dr. Murray Thelin Award (National Hemophilia Foundation), and an Outstanding Achievement Award for Contributions to Atherosclerosis Research (International Atherosclerosis Society). Among the projects Dr. Lawn led at CV Therapeutics was the first use of gene expression microarray profiling to discover the defective gene in a human inherited disease, Tangier disease. This work was selected as one of the year’s top ten breakthroughs of 1999 by the American Heart Association.
Jorge A. Leon, Ph.D., President/CEO, Leomics Associates, Inc.
Dr. Jorge Leon is internationally recognized for his pioneering work in molecular diagnostics. He earned a Ph.D. in Cellular and Molecular Biology from New York University, and completed his postdoctoral studies at the German Cancer Research Center in Heidelberg and Columbia University in New York City. Dr. Leon’s academic research focused on developing monoclonal antibody-based tumor marker assays and radio-immuno imaging devices which are currently in wide use. In the early 1990s, Dr. Jorge Leon transitioned into industry. As Quest Diagnostic’s Director of Molecular Diagnostics, Senior Director of Biotechnology Development, and Vice President of Applied Genomics, Dr. Leon spent twelve years developing molecular diagnostics strategies. In 2003, Dr. Leon founded Leomics Associates, Inc. a consulting firm committed to developing molecular diagnostics and personalized medicine (pharmacogenomics) in the United States and globally. Dr. Leon and his team specializes in identifying breakthrough opportunities and industry trends, and help start-up businesses, academic centers and established companies successfully build and commercialize innovative business strategies, product pipelines, and test menus.

Victoria Lunyak, Ph.D., Associate Professor, Buck Institute for Age Research
Dr. Victoria Lunyak joined the Buck Institute for Age Research in 2008, and studies epigenetics and aging with the goal of identifying methods for improving stem cell function with age which could improve tissue maintenance and repair in aged individuals and impact generation of stem cells for therapeutic purposes. Dr. Lunyak received a Master’s Degree in Biophysics from the Leningrad Polytechnic Institute in Russia and a Ph.D. in Molecular Biology from the St. Petersburg Nuclear Physics Institute at the Russian Academy of Science. She did postdoctoral work at Brown University and at the University of California, San Diego before becoming an adjunct assistant professor in the Department of Medicine at the University of California, San Diego.

Dr. Kyle MacBeth, Director of Translational Development, Celgene Corporation
Dr. MacBeth has expertise in the epigenetics of cancer and epigenetic therapies. He received his Ph.D. in microbiology and molecular genetics from Harvard University, and has spent the last 15 years in the biopharmaceutical industry focused on cancer drug discovery and development. He began his professional career as a research scientist in the oncology franchise of Millennium Pharmaceuticals identifying and validating new cancer targets, and holding leadership roles in several non-clinical drug development programs. Dr. MacBeth currently leads the clinical and non-clinical translational research for Celgene’s Vidaza, oral azacitidine and Revlimid myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) programs.

Dr. Arturo Orjalo, Scientist at Biosearch Technologies
Dr. Orjalo received his Ph.D. from the University of California, San Diego. His postdoctoral work took place at the Buck Institute for Research on Aging in Dr. Judith Campisi’s laboratory where significant contributions to understanding aging, cellular senescence, and numerous age-related diseases such as cancer and neurodegenerative disorders have been made. Dr. Orjalo has a broad molecular and cell biology background, and is currently focused on the development of Stellaris technology.

Dr. Michael Synder, Stanford Ascherman Professor, Chair of Genetics, Director of the Center of Genomics and Personalized Medicine
Dr. Synder is a leader in the field of functional genomics and proteomics. His laboratory was the first to perform a large-scale functional genomics project in any organism, and has launched many technologies in genomics and proteomics including the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor binding, paired end
sequencing for mapping of structural variation in eukaryotes, and RNA-Seq. These technologies have been used for characterizing genomes, proteomes and regulatory networks.

**Dr. Yuzhuo Wang**, Senior Scientist, Vancouver Prostate Centre and BC Cancer Agency

Dr. Wang is the Founder of the Living Tumor Laboratory and an Associate Professor in the Department of Urological Sciences at the University of British Columbia (UBC). In addition to proposing novel hypotheses on prostate stem cell and epithelial-immune cell transition, he is responsible for a novel method for establishing transplantable, patient-derived xenograft models that closely resemble patients' malignancies. His laboratory has developed over 170 transplantable tumor tissue lines. Dr. Wang is the recipient of numerous awards the Roche (Canada) Translation Research Award, Overseas Chinese Scholars Award, ICARE Innovative Scholar Award and the UBC Faculty of Medicine Distinguished Achievement Award.